Tresiba insulin degludec APPROVED
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Launch2015-09-25
Peak Sales Est$3500M
Formulations[{"id":"tresiba-sc","doses":"100 U/mL, 200 U/mL","notes":"Ultra-long-acting basal insulin","route":"
Companies
NVO (ORIGINATOR)100%
Mechanism: Insulin analog
Expert: Recombinant insulin analog with modified amino acid sequence or formulation to optimize pharmacokinetic profile for basal, prandial, or combination glycemic control.
Everyday: A modified version of insulin that helps the body use blood sugar for energy, designed to work faster or longer than natural insulin.
Targets: ["INSR"]
Revenue History
PeriodRevenue ($M)
2025$2,800M
Data from Supabase · Updated 2026-03-24